seroconverted – Communicable Diseases Research

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라

Article

Published on 2022-12-012022-09-11
Journal: Virulence
[Category] COVID19(2023년), SARS, 진단, 치료법,

Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in children

Article

Published on 2022-11-012022-11-15
Journal: Microbiological research
[Category] COVID19(2023년), SARS, 진단, 치료기술,

Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays

Article

Published on 2022-11-012022-11-15
Journal: Journal of Clinical Virology
[Category] SARS, 진단,

[키워드] Abbott Accuracy antibodies antibody Antibody Response Antibody titer Architect BAU BNT162b2 ChAdOx1-S collected comparable correlation COVID-19 DiaSorin effective Elecsy elicited Genscript greater IgG immune response Immunoglobulin indicated individual International LIAISON Moderna mRNA-1273 naïve Neutralizing antibody titer Oxford-AstraZeneca Pfizer/BioNTech plasma protective immunity Quantitative Quantitative serological assays ranged regression analysis response Roche SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination sensitivity seroconverted serological serological response significantly higher specificity Standard tested the WHO unit Vaccine Vaccines virus neutralization assays WHO WHO international standard. World Health Organization
[DOI] 10.1016/j.jcv.2022.105292 PMC 바로가기

Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

Article

Published on 2022-10-242022-11-15
Journal: Revista da Sociedade Brasileira de Medicina Tropic
[Category] COVID19(2023년), SARS, 진단,

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Article

Published on 2022-10-042022-11-15
Journal: PLoS Pathogens
[Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] Activation antibody Antibody Response Antibody titre antigen exposure baseline benefit binding BNT162b2 boost CD4+ T cell CD8+ Cellular immune response clinical trial Course COVID-19 Delta dose ELISA ELISPOT enhanced global public health glycoprotein Heterologous highest humoral immune memory immune response immunological increase in individual majority marker median mRNA mRNA COVID-19 vaccine mRNA vaccination mRNA vaccine naïve natural infection neutralising antibody titre omicron participant Participants PCR proportion question receiving recruited response RNA SARS-CoV-2 vaccine second dose seroconverted significantly higher subject the SARS-CoV-2 titre vaccination Vaccination strategy Vaccine variants were measured wildtype
[DOI] 10.1371/journal.ppat.1010885 PMC 바로가기

Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis

Article

Published on 2022-10-012022-11-15
Journal: Joint bone spine
[Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome addition Antibody Response biologic Cohort cohort study conducted coronavirus COVID-19 COVID-19 pandemic disease evaluated identify IgG antibody immune-mediated diseases impair individuals Inflammatory Inflammatory rheumatic diseases IQR leflunomide less management median age Meta-analysis methotrexate observational study Older participant Patient performed Prevalence reported rheumatic disease rituximab robust Sample size SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV2 vaccination second vaccination seroconversion rate seroconversion rate. seroconverted serological response significantly Spike protein suggested targeted therapy Therapies therapy treated two-dose regimen vaccination Vaccine were measured
[DOI] 10.1016/j.jbspin.2022.105380 PMC 바로가기

Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]

Article

Published on 2022-09-082022-11-15
Journal: Journal of Crohn's & colitis
[Category] SARS, 진단,

[키워드] Affect Against antagonists anti-SP IgG Anti-spike anti-TNF anti-tumour necrosis factor antagonists. Antibody Response booster vaccination bowel Cohort Complete COVID-19 COVID-19 vaccination determine Diagnosis diminished healthy control highlight IBD Immunoglobulin Impaired Inflammatory bowel disease inhibitor investigated medication mRNA vaccine Necrosis Patient Protein Quantitative receiving recruited response response to vaccination Result SARS-CoV-2 vaccination seroconvert seroconverted serological response significantly lower therapy TNF TNF antagonist Treatment vaccination vaccination against COVID-19 Vaccine vaccine response were assessed
[DOI] 10.1093/ecco-jcc/jjac029 PMC 바로가기

Serologic Status and SARS-CoV-2 Infection over 6 Months of Follow Up in Healthcare Workers in Chicago: A Cohort Study

Article

Published on 2022-09-012022-11-15
Journal: Infection Control and Hospital Epidemiology
[Category] SARS, 진단,

[키워드] 95% confidence interval Abbott adjusted analyzed anti-Nucleocapsid IgG antibody status baseline Baseline serology baseline serostatus changes in checked Chicago cohort study coronavirus disease COVID-19 criteria demographics determine Follow-up HCW HCWs healthcare worker identify Infection median moderate Month participant PCR PCR positive polymerase chain positive positive PCR Prospective recruited Reinfection Respiratory Coronavirus risk SARS-CoV-2 SARS-COV-2 infection seroconverted serologic serology serology testing seronegative seronegative participant seropositive Seropositivity setting status virus was used were assessed worker
[DOI] 10.1017/ice.2021.367 PMC 바로가기

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

Clinical Trial

Published on 2022-09-012022-10-05
Journal: The Lancet. Infectious Diseases
[Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal
[DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study

COVID-19 백신 접종 후 항-CD20 치료 환자의 강력한 T-세포 반응: 전향적 코호트 연구

Observational Study

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat
[Category] SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus anti-CD20 anti-CD20 therapy anti-CD20 treatment antibodies antibody Antibody Response Arthritis Breakthrough infection CD20 CD4 CD4 T cell CD8 T cell CD8 T cells cohort study Complication Control controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine detectable dose Effectiveness effector molecule effector molecules expressed Follow-up had no humoral humoral responses individual Mild mRNA COVID-19 vaccines mRNA-based COVID-19 vaccine multiple sclerosis Ocrelizumab Patient patients treated Prospective prospective observational cohort reduction respiratory response response rate response rates rheumatic disease Rheumatic diseases rheumatoid arthritis rheumatoid arthritis. risk rituximab seroconverted severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe coronavirus disease severe COVID-19 significantly lower specific antibodies spike T cell T cells T-cell T-cell Response T-cell responses Th1 phenotype treated treated patient vaccination
[DOI] 10.1093/cid/ciab954 PMC 바로가기 [Article Type] Observational Study